BD announces commercial availability of CE-marked PAXgene Blood DNA Tube in Europe

BD Launches the PAXgene^® Blood DNA Tube in Europe

BD (Becton, Dickinson and Company), a leading global medical technology company, today announced the commercial availability of the CE-marked PAXgene^® Blood DNA Tube in Europe. The PAXgene^® Blood DNA Tube is the first blood collection tube designed specifically for in vitro diagnostic (IVD) genomic DNA testing. The product was developed by PreAnalytiX GmbH, a joint venture between BD and QIAGEN.

DNA testing has advanced significantly since the publication of the first draft of the human genome in 2000. While swab and saliva samples are popular, blood remains the sample of choice for clinical diagnostic testing and identification of new biomarkers for disease research.

To improve the collection of DNA in these applications, the PAXgene^® Blood DNA Tube performance has been comprehensively analysed. “The validated performance data we provide to clinical scientists for the PAXgene^® Blood DNA Tube should reduce the chances of preanalytical error, ensuring the best quality sample for accurate IVD test performance and for blood DNA storage related to the identification of new biomarkers of disease or drug actions,” comments Frank Augello, General Manager, PreAnalytiX GmbH.

The PAXgene^® Blood DNA Tube is a 2.5 ml blood collection tube that stabilizes genomic DNA with validated time and temperature parameters. The tube incorporates workflow efficiency features including a 2D bar code on the label and a tube closure that clearly identifies this unique DNA tube.

The PAXgene^® Blood DNA Tube is a constituent of a complete molecular diagnostic portfolio of PreAnalytiX GmbH products comprising DNA isolation kits, automation and analysis equipment. The initial target customers for the PAXgene® Blood DNA Tube are those requiring validated high quality blood DNA - blood DNA testing laboratories and biorepositories.